Below is the current list of studies covered by the CIRB. It includes both Available to Open and Completed studies. Study documents approved after July 1, 2013 for all covered studies are available on the CTSU website.
To request documents approved before July 1, 2013, please contact the CIRB Helpdesk.
|Study Number||Lead Group||Study Title||CIRB||Study Status|
|NSABP-B-34||NSABP||A Clinical Trial Comparing Adjuvant Clodronate Therapy vs. Placebo in Early-Stage Breast Cancer Patients Receiving Systemic Chemotherapy and/or Hormonal Therapy or No Therapy||Adult CIRB - Late Phase Emphasis||Completed|
|ACCL0935||COG||Prevention of Cancer/Treatment-Related Weight Loss in Children at High Nutritional Risk||Pediatric CIRB||Completed|
|N0949||NCCTG||Randomized Phase III Trial of mFOLFOX7 or XELOX Plus Bevacizumab Versus 5-Fluorouracil/Leucovorin or Capecitabine Plus Bevacizumab as First-line Treatment in Elderly Patients with Metastatic Colorectal Cancer||Adult CIRB - Late Phase Emphasis||Completed|
|S0232||SWOG||Double-Blinded Placebo Controlled Phase III Trial Comparing Dexamethasone (DEX) to the Combination of DEX + CC-5013 in Patients with Previously Untreated Multiple Myeloma who are Not Immediately Undergoing Autologous Stem Cell Transplant||Adult CIRB - Late Phase Emphasis||Completed|
|CALGB-80303||CALGB||A Randomized Phase III Trial of Gemcitabine Plus Bevacizumab (NSC #704865 IND# 7921) Versus Gemcitabine Plus Placebo in Patients with Advanced Pancreatic Cancer||Adult CIRB - Late Phase Emphasis||Completed|
|RTOG-BR-0118||RTOG||A Phase III Study of Conventional Radiation Therapy Plus Thalidomide (NSC# 66847) Versus Conventional Radiation Therapy For Multiple Brain Metastases||Adult CIRB - Late Phase Emphasis||Completed|
|ARST08P1||COG||A Pilot Study to Evaluate Novel Agents (Temozolomide and Cixutumumab [IMC-A12; Anti-IGF-IR Monoclonal Antibody; IND #100947; NSC # 742460]) in Combination with Intensive Multi-Agent Interval Compressed Therapy for Patients with High-Risk Rhabdomyosarcoma: A Groupwide Pilot Study||Pediatric CIRB||Completed|
|GOG-0241||GOG||A GCIG Intergroup Multicenter Phase III Trial of Open Label Carboplatin and Paclitaxel +/- NCI-Supplied Agent: Bevacizumab (NSC #704865; IND #113912) Compared With Oxaliplatin and Capecitabine +/- Bevacizumab as First Line Chemotherapy in Patients with Mucinous Epithelial Ovarian or Fallopian Tube Cancer (MEOC)||Adult CIRB - Late Phase Emphasis||Completed|
|S0600||SWOG||Phase III Trial of Irinotecan-Based Chemotherapy Plus Cetuximab (NSC-714692) or Bevacizumab (NSC-704865) as Second-Line Therapy for Patients with Metastatic Colorectal Cancer who have Progressed on Bevacizumab with either FOLFOX; OPTIMOX or XELOX||Adult CIRB - Late Phase Emphasis||Completed|
|E2902||ECOG||A Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission After Primary Induction Failure or Patients over Age 60 in First Remission||Adult CIRB - Late Phase Emphasis||Completed|